The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease
Open accessAbstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by an incompletely reversible limitation in airflow. A physiological variable--the forced expiratory volume in one second (FEV1)--is often used to grade the severity of COPD. However, patients with COPD have systemic manifestations that are not reflected by the FEV1. We hypothesized that a multidimensional grading system that assessed the respiratory and systemic expressions of COPD would better categorize and predict outcome in these patients. METHODS: We first evaluated 207 patients and found that four factors predicted the risk of death in this cohort: the body-mass index (B), the degree of airflow obstruction (O) and dyspnea (D), and exercise capacity (E), measured by the six-minute-walk test. We used these variables to construct the BODE index, a multidimensional 10-point scale in which higher scores indicate a higher risk of death. We then prospectively validated the index in a cohort of 625 patients, with death from any cause and from respiratory causes as the outcome variables. RESULTS: There were 25 deaths among the first 207 patients and 162 deaths (26 percent) in the validation cohort. Sixty-one percent of the deaths in the validation cohort were due to respiratory insufficiency, 14 percent to myocardial infarction, 12 percent to lung cancer, and 13 percent to other causes. Patients with higher BODE scores were at higher risk for death; the hazard ratio for death from any cause per one-point increase in the BODE score was 1.34 (95 percent confidence interval, 1.26 to 1.42; P<0.001), and the hazard ratio for death from respiratory causes was 1.62 (95 percent confidence interval, 1.48 to 1.77; P<0.001). The C statistic for the ability of the BODE index to predict the risk of death was larger than that for the FEV1 (0.74 vs. 0.65). CONCLUSIONS: The BODE index, a simple multidimensional grading system, is better than the FEV1 at predicting the risk of death from any cause and from respiratory causes among patients with COPD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [166]
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [42]
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [42]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., & HURD, S. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2101039 · Cited by 6,587
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Mortality by cause for eight regions of the world: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07493-4 · Cited by 4,043
Lung Function Testing: Selection of Reference Values and Interpretative Strategies
(1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.5.1202 · Cited by 2,510
NOCTURNAL OXYGEN THERAPY TRIAL GROUP* (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-391 · Cited by 2,218
Evaluation of Clinical Methods for Rating Dyspnea
Mahler, D. A., & Wells, C. K. (1988) · Chest · doi:10.1378/chest.93.3.580 · Cited by 1,822
Research works printed but not linked: 1
- Burrows B, 1991, Eur Respir Rev, 1, 340
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Spruit, M. A., Singh, S. J., Garvey, C., ZuWallack, R., Nici, L., Rochester, C., Hill, K., Holland, A. E., Lareau, S. C., Man, W. D.-C., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1634st · Cited by 3,938
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
“The BODE (Body mass index, Obstruction, Dyspnea, and Exercise) method gives a composite score that is a better predictor of subsequent survival than any single component.(71) Simpler alternatives that do not include exercise testing need validation to confirm suitability for routine clinical use.”
MethodSelf-citationGlobal burden of COPD: risk factors, prevalence, and future trends
Mannino, D. M., & Buist, A. S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61380-4 · Cited by 2,079
Tufford (2017) · doi:10.1007/s · Cited by 2,003
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation
Nici, L., Donner, C., Wouters, E., Zuwallack, R., Ambrosino, N., Bourbeau, J., Carone, M., Celli, B., Engelen, M., Fahy, B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200508-1211st · Cited by 1,966
Self-citationSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Soler-Cataluna, J. J. (2005) · Thorax · doi:10.1136/thx.2005.040527 · Cited by 1,931
Systemic manifestations and comorbidities of COPD
Barnes, P. J., & Celli, B. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00128008 · Cited by 1,820
Self-citationParshall, M. B., Schwartzstein, R. M., Adams, L., Banzett, R. B., Manning, H. L., Bourbeau, J., Calverley, P. M., Gift, A. G., Harver, A., Lareau, S. C., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201111-2042st · Cited by 1,844
Cause-Specific Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Gail, M. H. (2007) · JAMA · doi:10.1001/jama.298.17.2028 · Cited by 1,542
Weill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329
Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease
Divo, M., Cote, C., de Torres, J. P., Casanova, C., Marin, J. M., Pinto-Plata, V., Zulueta, J., Cabrera, C., Zagaceta, J., Hunninghake, G., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201201-0034oc · Cited by 1,275
“7 and all BODE quartiles were represented (Table 1) (9).”
BackgroundMethodResultInfluentialSelf-citationA Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Characterisation of COPD heterogeneity in the ECLIPSE cohort
the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators, Agusti, A., Calverley, P. M., Celli, B., Coxson, H. O., Edwards, L. D., Lomas, D. A., MacNee, W., Miller, B. E., Rennard, S., et al. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-122 · Cited by 1,157
“The BODE index was calculated according to Celli et al [5].”
BackgroundMethodSelf-citationOrens, J. B., Estenne, M., Arcasoy, S., Conte, J. V., Corris, P., Egan, J. J., Egan, T., Keshavjee, S., Knoop, C., Kotloff, R., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.03.011 · Cited by 1,073
Chronic Obstructive Pulmonary Disease Phenotypes: The Future of COPD
Han, M. K., Agusti, A., Calverley, P. M., Celli, B. R., Criner, G., Curtis, J. L., Fabbri, L. M., Goldin, J. G., Jones, P. W., MacNee, W., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200912-1843cc · Cited by 1,032
“Perhaps best well known of these is the BODE Index to predict mortality, which incorporates dyspnea, BMI, FEV1, and exercise capacity as measured by 6-minute walk distance (6MWD).”
BackgroundMethodInfluentialSelf-citationSystemic effects of chronic obstructive pulmonary disease
Agustí, A. G. N., Noguera, A., Sauleda, J., Sala, E., Pons, J., & Busquets, X. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00405703 · Cited by 1,045
Mortality in COPD: role of comorbidities
Sin, D. D., Anthonisen, N. R., Soriano, J. B., & Agusti, A. G. (2006) · European Respiratory Journal · doi:10.1183/09031936.00133805 · Cited by 1,052
Burden and clinical features of chronic obstructive pulmonary disease (COPD)
Pauwels, R. A., & Rabe, K. F. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16855-4 · Cited by 1,004
Chronic obstructive pulmonary disease
Decramer, M., Janssens, W., & Miravitlles, M. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60968-9 · Cited by 972
Physical Activity Is the Strongest Predictor of All-Cause Mortality in Patients With COPD
Waschki, B., Kirsten, A., Holz, O., Müller, K.-C., Meyer, T., Watz, H., & Magnussen, H. (2011) · Chest · doi:10.1378/chest.10-2521 · Cited by 951
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Self-citationAgustí, A., Edwards, L. D., Rennard, S. I., MacNee, W., Tal-Singer, R., Miller, B. E., Vestbo, J., Lomas, D. A., Calverley, P. M. A., Wouters, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037483 · Cited by 848
“The BODE index was calculated as previously described [23].”
MethodSelf-citationOutcomes for COPD pharmacological trials: from lung function to biomarkers
Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00099306 · Cited by 858
Self-citationBaumann, P., Nyman, J., Hoyer, M., Wennberg, B., Gagliardi, G., Lax, I., Drugge, N., Ekberg, L., Friesland, S., Johansson, K.-A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.5681 · Cited by 836
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Body composition and mortality in chronic obstructive pulmonary disease
Schols, A. M., Broekhuizen, R., Weling-Scheepers, C. A., & Wouters, E. F. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.1.53 · Cited by 658
“On the basis of numerous reports showing an association between BMI and mortality risk in COPD, Celli at al (26) recently proposed that clinical staging for COPD should be based not only on spirometry and resting arterial blood gases, eg, the recent GOLD criteria, but also on BMI, exercise capacity, and dyspnea score.”
BackgroundSuissa, S., Dell'Aniello, S., & Ernst, P. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201518 · Cited by 779
Vogelmeier, C. F., Criner, G. J., Martínez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.02.001 · Cited by 309
Self-citationEvaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)
Vestbo, J., Anderson, W., Coxson, H. O., Crim, C., Dawber, F., Edwards, L., Hagan, G., Knobil, K., Lomas, D. A., MacNee, W., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00111707 · Cited by 759
“Finally, although FEV1 as well as other measures of lung function can be used for prognostic purposes, the association between mortality and FEV1 is considerably stronger when other measures are added to the predictive equation (10).”
BackgroundChronic obstructive pulmonary disease
Barnes, P. J., Burney, P. G. J., Silverman, E. K., Celli, B. R., Vestbo, J., Wedzicha, J. A., & Wouters, E. F. M. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.76 · Cited by 734
Self-citationCelli, B. R., Thomas, N. E., Anderson, J. A., Ferguson, G. T., Jenkins, C. R., Jones, P. W., Vestbo, J., Knobil, K., Yates, J. C., & Calverley, P. M. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200712-1869oc · Cited by 748
“This suggests an important association between systemic consequences of the disease and disease progression in the lungs ( 33 , 34), but does not necessarily indicate causality.”
BackgroundSelf-citationSwallow, E. B., Reyes, D., Hopkinson, N. S., Man, W. D.-C., Porcher, R., Cetti, E. J., Moore, A. J., Moxham, J., & Polkey, M. I. (2007) · Thorax · doi:10.1136/thx.2006.062026 · Cited by 728
“The endpoint measured was death or lung transplantation and median (range) follow up was 38 (1-54) months.”
BackgroundResultLanken, P. N., Terry, P. B., DeLisser, H. M., Fahy, B. F., Hansen-Flaschen, J., Heffner, J. E., Levy, M., Mularski, R. A., Osborne, M. L., Prendergast, T. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200605-587st · Cited by 713
“Although the BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index provides prognostic information over periods of time from 12 to 52 months, it has not been validated for determining a risk of mortality greater than 50% at a 6-month time period needed to qualify for hospice care (58).”
Recommendations on the use of exercise testing in clinical practice
Palange, P., Ward, S. A., Carlsen, K.-H., Casaburi, R., Gallagher, C. G., Gosselink, R., O'Donnell, D. E., Puente-Maestu, L., Schols, A. M., Singh, S., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00046906 · Cited by 718
Physical Activity and Hospitalization for Exacerbation of COPD
Pitta, F., Troosters, T., Probst, V. S., Spruit, M. A., Decramer, M., & Gosselink, R. (2006) · Chest · doi:10.1378/chest.129.3.536 · Cited by 688
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Respirology · doi:10.1111/resp.13012 · Cited by 681
Self-citationPhysical activity in patients with COPD
Watz, H., Waschki, B., Meyer, T., & Magnussen, H. (2009) · European Respiratory Journal · doi:10.1183/09031936.00024608 · Cited by 684
O’Donnell, D. E., Aaron, S., Bourbeau, J., Hernandez, P., Marciniuk, D. D., Balter, M., Ford, G., Gervais, A., Goldstein, R., Hodder, R., et al. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/830570 · Cited by 693
“a global score (eg, the BODE index [108]) or identified indi-”
BackgroundComplex chronic comorbidities of COPD
Fabbri, L. M., Luppi, F., Beghé, B., & Rabe, K. F. (2008) · European Respiratory Journal · doi:10.1183/09031936.00114307 · Cited by 660
Vestbo, J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200505-969oc · Cited by 327
“For these reasons, BMI has been suggested as one of four parameters suitable for staging COPD (6).”
BackgroundPulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease
Troosters, T., Casaburi, R., Gosselink, R., & Decramer, M. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200408-1109so · Cited by 649
“In patients with pulmonary disease, disease severity and prognosis are determined not only by lung function impairment (1, 2).”
From COPD to chronic systemic inflammatory syndrome?
Fabbri, L. M., & Rabe, K. F. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61383-x · Cited by 635
Pulmonary rehabilitation in chronic obstructive pulmonary disease
Elkhateeb, N. B., Elhadidi, A. A., Masood, H. H., & Mohammed, A. R. (2015) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.1016/j.ejcdt.2015.03.001 · Cited by 622
Lim, J. U., Lee, J. H., Kim, J. S., Hwang, Y. I., Kim, T.-H., Lim, S. Y., Yoo, K. H., Jung, K.-S., Kim, Y. K., & Rhee, C. K. (2017) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s141295 · Cited by 549
Casanova, C., Cote, C., de Torres, J. P., Aguirre-Jaime, A., Marin, J. M., Pinto-Plata, V., & Celli, B. R. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-867oc · Cited by 597
Self-citationLamprecht, B., McBurnie, M. A., Vollmer, W. M., Gudmundsson, G., Welte, T., Nizankowska-Mogilnicka, E., Studnicka, M., Bateman, E., Anto, J. M., Burney, P., et al. (2011) · Chest · doi:10.1378/chest.10-1253 · Cited by 526
Raherison, C., & Girodet, P.-O. (2009) · European Respiratory Review · doi:10.1183/09059180.00003609 · Cited by 514
Miravitlles, M. (2004) · Thorax · doi:10.1136/thx.2003.008730 · Cited by 557
“27 In contrast to the SGRQ results, the generic questionnaire SF-12 did not detect any significant change during follow up.”
Cavaillès, A., Brinchault-Rabin, G., Dixmier, A., Goupil, F., Gut-Gobert, C., Marchand-Adam, S., Meurice, J.-C., Morel, H., Person-Tacnet, C., Leroyer, C., et al. (2013) · European Respiratory Review · doi:10.1183/09059180.00008612 · Cited by 510
Minimal Clinically Important Differences in COPD Lung Function
Donohue, J. F. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200053377 · Cited by 529
“Tiotropium Salmeterol Placebo Trough response (ml): Day 169–15 13 [13] 14 [13] 35 [13] Peak response (ml): Day 169–1 20 [15]** 44 [16] 56 [15] Day 169–15 21 [13] 26 [14] 26 [13] Average 0–4 h (ml): Day 169–1 22 [14]* 32 [15] 50 [14] Day 169–15 21 [12] 13 [13] 25 [12] Average 4–8 h (ml): Day 169–1 1 [14] 25 [15] 68 [14…”
Puhan, M. A., Garcia-Aymerich, J., Frey, M., ter Riet, G., Antó, J. M., Agustí, A. G., Gómez, F. P., Rodríguez-Roisín, R., Moons, K. G., Kessels, A. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61301-5 · Cited by 521
The prevalence of quadriceps weakness in COPD and the relationship with disease severity
Seymour, J. M., Spruit, M. A., Hopkinson, N. S., Natanek, S. A., Man, W. D.-C., Jackson, A., Gosker, H. R., Schols, A. M. W. J., Moxham, J., Polkey, M. I., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00104909 · Cited by 411
Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score
Martínez-García, M. Á., de Gracia, J., Vendrell Relat, M., Girón, R.-M., Máiz Carro, L., de la Rosa Carrillo, D., & Olveira, C. (2014) · European Respiratory Journal · doi:10.1183/09031936.00026313 · Cited by 503
Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease
Celli, B. R., & Wedzicha, J. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1900500 · Cited by 461
Self-citationComorbidities in Chronic Obstructive Pulmonary Disease
Chatila, W. M., Thomashow, B. M., Minai, O. A., Criner, G. J., & Make, B. J. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200709-148et · Cited by 478
“Celli and colleagues (119) United States, Spain,”
Association Between Interstitial Lung Abnormalities and All-Cause Mortality
Putman, R. K., Hatabu, H., Araki, T., Gudmundsson, G., Gao, W., Nishino, M., Okajima, Y., Dupuis, J., Latourelle, J. C., Cho, M. H., et al. (2016) · JAMA · doi:10.1001/jama.2016.0518 · Cited by 473
Self-citationExacerbations of chronic obstructive pulmonary disease
Celli, B. R., & Barnes, P. J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00109906 · Cited by 462
Self-citationHan, M. K., Kazerooni, E. A., Lynch, D. A., Liu, L. X., Murray, S., Curtis, J. L., Criner, G. J., Kim, V., Bowler, R. P., Hanania, N. A., et al. (2011) · Radiology · doi:10.1148/radiol.11110173 · Cited by 453
Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort
Miller, J., Edwards, L. D., Agustí, A., Bakke, P., Calverley, P. M. A., Celli, B., Coxson, H. O., Crim, C., Lomas, D. A., Miller, B. E., et al. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.05.001 · Cited by 437
“The BODE index was calculated according to Celli et al.(24) All subjects underwent a low-dose computed tomography (CT) scan of the chest acquired using multi-detectorrow CT scanners (GE Healthcare or Siemens Healthcare) with a minimum of 4 rows, obtained in the supine position, at suspended full inspiration, without a…”
MethodSelf-citationBTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults
Davidson, A. C., Banham, S., Elliott, M., Kennedy, D., Gelder, C., Glossop, A., Church, A. C., Creagh-Brown, B., Dodd, J. W., Felton, T., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-208209 · Cited by 426
Agarwala, P., & Salzman, S. H. (2020) · Chest · doi:10.1016/j.chest.2019.10.014 · Cited by 394
“Each one-point increment in the BODE Index increases the HR for death from any cause by 1.(4) An”
BackgroundPredictors of Mortality in Patients with Emphysema and Severe Airflow Obstruction
Martinez, F. J., Foster, G., Curtis, J. L., Criner, G., Weinmann, G., Fishman, A., DeCamp, M. M., Benditt, J., Sciurba, F., Make, B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1677oc · Cited by 446
“The BODE (Body mass index, airflow Obstruction, Dyspnea, Exercise capacity) index is an 11-point composite score (0–10) in which higher scores indicate poorer outcomes (4).”
BackgroundMethodResultInfluentialChronic Obstructive Pulmonary Disease
Labaki, W. W., & Rosenberg, S. R. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202008040 · Cited by 376
Celli, B. R., Locantore, N., Yates, J., Tal-Singer, R., Miller, B. E., Bakke, P., Calverley, P., Coxson, H., Crim, C., Edwards, L. D., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1792oc · Cited by 432
“The BODE index was calculated as previously reported (8).”
BackgroundMethodSelf-citationC-reactive protein in patients with COPD, control smokers and non-smokers
Pinto-Plata, V. M. (2005) · Thorax · doi:10.1136/thx.2005.042200 · Cited by 435
“5 CRP is a marker of inflammation that has been associated with an increased risk of incident myocardial infarction, stroke, unstable angina, and sudden coronary death.”
BackgroundSelf-citationA Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation
The Long-Term Oxygen Treatment Trial Research Group (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604344 · Cited by 428
Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement
Puente-Maestu, L., Palange, P., Casaburi, R., Laveneziana, P., Maltais, F., Neder, J. A., O'Donnell, D. E., Onorati, P., Porszasz, J., Rabinovich, R., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00745-2015 · Cited by 412
The clinical features of the overlap between COPD and asthma
the COPDGene Investigators, Hardin, M., Silverman, E. K., Barr, R. G., Hansel, N. N., Schroeder, J. D., Make, B. J., Crapo, J. D., & Hersh, C. P. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-127 · Cited by 428
“Measures of disease severity included healthrelated quality of life as determined by the St George’s Respiratory Questionnaire (SGRQ) [16], predicted mortality using the BODE index (Body mass index, airflow obstruction, dyspnea and exercise capacity index) [17], history of hay fever, respiratory medication use, and hi…”
MethodThe effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies
Poulain, M. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.051299 · Cited by 415
“In fact, most CMAJ • April 25, 2006 • 174(9) | 1295 studies focus on undernourished patients with COPD.”
BackgroundInfluentialDesign of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): Table 1
Couper, D., LaVange, L. M., Han, M., Barr, R. G., Bleecker, E., Hoffman, E. A., Kanner, R., Kleerup, E., Martinez, F. J., Woodruff, P. G., et al. (2014) · Thorax · doi:10.1136/thoraxjnl-2013-203897 · Cited by 394
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease
Man, S. F. P. (2006) · Thorax · doi:10.1136/thx.2006.059808 · Cited by 397
Kemp, S. V., Slebos, D.-J., Kirk, A., Kornaszewska, M., Carron, K., Ek, L., Broman, G., Hillerdal, G., Mal, H., Pison, C., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1327oc · Cited by 390
“A reduction of more than 1 point in the BODE index has been associated with a significant decrease in mortality (30, 31) and the difference between groups in the change in BODE index in this prospective trial was 21.”
BackgroundSteer, J., Gibson, J., & Bourke, S. C. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-202103 · Cited by 388
Miravitlles, M., Soler-Cataluña, J. J., Calle, M., Molina, J., Almagro, P., Quintano, J. A., Trigueros, J. A., Cosío, B. G., Casanova, C., Antonio Riesco, J., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.03.018 · Cited by 378
Self-citationSeymour, J. M., Ward, K., Sidhu, P. S., Puthucheary, Z., Steier, J., Jolley, C. J., Rafferty, G., Polkey, M. I., & Moxham, J. (2009) · Thorax · doi:10.1136/thx.2008.103986 · Cited by 370
Interpretation of treatment changes in 6-minute walk distance in patients with COPD
Puhan, M. A., Mador, M. J., Held, U., Goldstein, R., Guyatt, G. H., & Schünemann, H. J. (2008) · European Respiratory Journal · doi:10.1183/09031936.00140507 · Cited by 373
Watz, H., Waschki, B., Boehme, C., Claussen, M., Meyer, T., & Magnussen, H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-1011oc · Cited by 368
“We used multivariate linear regression analysis, the clinical stages of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) (8), and the BODE (body mass index, airway obstruction, dyspnea, and exercise capacity) index (15) to analyze the data.”
MethodInfluentialLange, P., Marott, J. L., Vestbo, J., Olsen, K. R., Ingebrigtsen, T. S., Dahl, M., & Nordestgaard, B. G. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1299oc · Cited by 362
McKenzie, D. K., & Frith, P. A. (2003) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05213.x · Cited by 369
Lehouck, A., Mathieu, C., Carremans, C., Baeke, F., Verhaegen, J., Van Eldere, J., Decallonne, B., Bouillon, R., Decramer, M., & Janssens, W. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-2-201201170-00004 · Cited by 363
“Baseline characteristics included the Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index, a multidimensional, COPD-specific, 10-point scale in which higher scores indicate a higher risk for death (22), and the Charlson comorbidity index, a non–COPD-specific but validated comorbidity inde…”
BackgroundSex Differences in Severe Pulmonary Emphysema
Martinez, F. J., Curtis, J. L., Sciurba, F., Mumford, J., Giardino, N. D., Weinmann, G., Kazerooni, E., Murray, S., Criner, G. J., Sin, D. D., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200606-828oc · Cited by 365
“multidimensional index (36), the mBODE (17), we also found that women exhibited higher scores than men.”
BackgroundClinical COPD phenotypes: a novel approach using principal component and cluster analyses
Burgel, P.-R., Paillasseur, J.-L., Caillaud, D., Tillie-Leblond, I., Chanez, P., Escamilla, R., Court-Fortune, I., Perez, T., Carré, P., & Roche, N. (2010) · European Respiratory Journal · doi:10.1183/09031936.00175109 · Cited by 358
“We calculated the multidimensional BOD index (B: Body mass index, O: obstruction (FEV1%), D: dyspnea evaluated on the modified Medical Research Council MMRC- scale), which was reported to be a better predictor of mortality than FEV1 [14, 15].”
MethodNutritional supplementation for stable chronic obstructive pulmonary disease
Ferreira, I. M., Brooks, D., White, J., & Goldstein, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000998.pub3 · Cited by 326
Casanova, C., Cote, C., Marin, J. M., Pinto-Plata, V., de Torres, J. P., Aguirre-Jaíme, A., Vassaux, C., & Celli, B. R. (2008) · Chest · doi:10.1378/chest.08-0520 · Cited by 341
Self-citationMartínez-García, M.-A., de la Rosa Carrillo, D., Soler-Cataluña, J.-J., Donat-Sanz, Y., Serra, P. C., Lerma, M. A., Ballestín, J., Sánchez, I. V., Selma Ferrer, M. J., Dalfo, A. R., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1518oc · Cited by 340
Hospitalized Exacerbations of COPD
Müllerova, H., Maselli, D. J., Locantore, N., Vestbo, J., Hurst, J. R., Wedzicha, J. A., Bakke, P., Agusti, A., & Anzueto, A. (2015) · Chest · doi:10.1378/chest.14-0655 · Cited by 320
Pulmonary rehabilitation and the BODE index in COPD
Cote, C. G., & Celli, B. R. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00045505 · Cited by 335
Self-citationMannino, D. M., Doherty, D. E., & Sonia Buist, A. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2005.03.035 · Cited by 326
Shortened Telomeres in Circulating Leukocytes of Patients with Chronic Obstructive Pulmonary Disease
Savale, L., Chaouat, A., Bastuji-Garin, S., Marcos, E., Boyer, L., Maitre, B., Sarni, M., Housset, B., Weitzenblum, E., Matrat, M., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200809-1398oc · Cited by 322
“The BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) Index score was calculated according to Celli and colleagues (22).”
MethodCOPD and its comorbidities: Impact, measurement and mechanisms
Negewo, N. A., Gibson, P. G., & McDonald, V. M. (2015) · Respirology · doi:10.1111/resp.12642 · Cited by 311
Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression
Suissa, S., Kezouh, A., & Ernst, P. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.06.019 · Cited by 317
Jaitovich, A., & Barreiro, E. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-2140ci · Cited by 303
“patients with COPD have worse outcomes (116, 118), the effect of obesity-driven higher BMI is a subject of controversy”
BackgroundWise, R. A., & Brown, C. D. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050527 · Cited by 308
“Recently, a group of investigators have validated a prediction score for the risk of death among patients with COPD that includes 6-minute walk distance as one of its four components with a value of less than 350 meters being associated with increased risk of death (27).”
BackgroundSepúlveda‐Loyola, W., Osadnik, C., Phu, S., Morita, A. A., Duque, G., & Probst, V. S. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12600 · Cited by 297
Brightling, C. E., Bleecker, E. R., Panettieri, R. A., Bafadhel, M., She, D., Ward, C. K., Xu, X., Birrell, C., & van der Merwe, R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70187-0 · Cited by 315
Exacerbations and Time Spent Outdoors in Chronic Obstructive Pulmonary Disease
Donaldson, G. C., Wilkinson, T. M. A., Hurst, J. R., Perera, W. R., & Wedzicha, J. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200408-1054oc · Cited by 316
“This could be due to ( 1 ) the patients’ poor physical fitness and muscle conditions, or (2 ) the difficulties in achieving the exercise intensities required to produce a meaningful gain in exercise capacity.”
BackgroundMethodInfluentialGarcia-Aymerich, J., Gomez, F. P., Benet, M., Farrero, E., Basagana, X., Gayete, A., Pare, C., Freixa, X., Ferrer, J., Ferrer, A., et al. (2011) · Thorax · doi:10.1136/thx.2010.154484 · Cited by 319
O’Brien, J. M., Phillips, G. S., Ali, N. A., Lucarelli, M., Marsh, C. B., & Lemeshow, S. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000202207.87891.fc · Cited by 314
Severe exacerbations and BODE index: Two independent risk factors for death in male COPD patients
Soler-Cataluña, J. J., Martínez-García, M. Á., Sánchez, L. S., Tordera, M. P., & Sánchez, P. R. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.12.005 · Cited by 309
Metadata
- Authors
- Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J.
- Affiliations
- Hospital Universitario Nuestra Señora de Candelaria (ES)
- Hospital Clínico Universitario de Caracas (VE)
- Boston University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-03-04
- Volume
- 350
- Issue
- 10
- Pages
- 1005-1012
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139347600
- Semantic Scholar
- 12606ed46f2e1cd6f56b679b445a8fda29690f65
- Cited by
- 4,015
- References
- 36
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 153 · 2023: 132 · 2022: 124 · 2021: 176 · 2020: 199 · 2019: 158 · 2018: 192 · 2017: 184 · 2016: 206 · 2015: 185 · 2014: 241 · 2013: 230 · 2012: 242
- FWCI
- 135.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
- Keywords
- chronic obstructive pulmonary disease, BODE index, body mass index, airflow obstruction, dyspnea, exercise capacity, 6-minute walk test, mortality prediction, FEV1, disease severity classification, respiratory mortality
- MeSH terms
- Aged, Airway Obstruction, Dyspnea, Forced Expiratory Volume, Humans, Middle Aged, Prospective Studies, Risk, Risk Factors, Severity of Illness Index, Body Mass Index, Exercise Tolerance, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.